Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DNLI Denali Therapeutics Inc.

Post-Mkt 07-02 18:42:55 EDT

25.83

-0.15

-0.58%

盘后26.00

+0.17+0.66%

17:26 EDT

High26.80	Low25.43	Vol1.54M
Open26.23	D1 Closing25.98	Amplitude5.27%
Mkt Cap4.10B	Tradable Cap3.72B	Total Shares158.59M
T/O39.82M	T/O Rate1.07%	Tradable Shares144.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DNLI","market":"US","secType":"STK","nameCN":"Denali Therapeutics Inc.","latestPrice":25.83,"timestamp":1783022400000,"preClose":25.98,"halted":0,"volume":1541147,"hourTrading":{"tag":"盘后","latestPrice":26,"preClose":25.83,"latestTime":"17:26 EDT","volume":45775,"amount":1182368.70775,"timestamp":1783027584727,"change":0.17,"changeRate":0.006581,"amplitude":0.017809},"delay":0,"changeRate":-0.005773672055427333,"floatShares":144000000,"shares":158591491,"eps":-2.878237,"marketStatus":"Post-Mkt","change":-0.15,"latestTime":"07-02 18:42:55 EDT","open":26.23,"high":26.8,"low":25.43,"amount":39821489.278155,"amplitude":0.052733,"askPrice":26,"askSize":1,"bidPrice":25.5,"bidSize":999,"shortable":3,"etf":0,"ttmEps":-2.878237,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783036800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1512709200000,"exchange":"NASDAQ","adjPreClose":25.98,"preHourTrading":{"tag":"盘前","latestPrice":26,"preClose":25.98,"latestTime":"09:27 EDT","volume":1049,"amount":27124.843739000004,"timestamp":1782998855985,"change":0.02,"changeRate":0.00077,"amplitude":0.014242},"postHourTrading":{"tag":"盘后","latestPrice":26,"preClose":25.83,"latestTime":"17:26 EDT","volume":45775,"amount":1182368.70775,"timestamp":1783027584727,"change":0.17,"changeRate":0.006581,"amplitude":0.017809},"volumeRatio":0.589307,"impliedVol":0.4157,"impliedVolPercentile":0.1195},"requestUrl":"/m/hq/s/DNLI","defaultTab":"news","newsList":[{"id":"2645698758","title":"Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2645698758","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645698758?lang=en_us&edition=fundamental","pubTime":"2026-06-24 10:27","pubTimestamp":1782268040,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI) has agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for US$195 million in cash. This is a material non-operational move that could influence liquidity and investor focus.\nSee our latest analysis for Denali Therapeutics.\nThe US$24.77 share price has been supported by strong recent momentum, with a 1-month share price return of 32.89% and a year-to-date share price return of 52.24%. However, the 5-year total shareholder return is down 67.78%,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-looks-fully-valued-after-195-millio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-looks-fully-valued-after-195-millio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4139","BK4548","DCF","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644086501","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2644086501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644086501?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:02","pubTimestamp":1781787741,"startTime":"0","endTime":"0","summary":"Healthcare stocks were advancing premarket Thursday, with the State Street Health Care Select Sector SPDR ETF  up 0.2% and the iShares Biotechnology ETF  0.5% higher.Denali Therapeutics  stock was up 1.8% after the company said it has signed an agreement to sell its rare pediatric disease priority review voucher for gross proceeds of $195 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4585","XLV","IE00B64PRP62.GBP","IE0034235188.USD","LU0061475181.USD","BK4581","IE00BGHQF748.EUR","BK4139","BK4588","FDN","LU1894683348.USD","IBB","IE00B3QW5Z07.USD","XBI","STT","BK4548","BK4550","LABU","BK4135","LU1883839398.USD","LU1894683264.USD","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083214","title":"Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083214","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083214?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:14","pubTimestamp":1781784895,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI) announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher, PRV, fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-enters-agreement-to-sell-rare-pediatric-disease-prv-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-enters-agreement-to-sell-rare-pediatric-disease-prv-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DNLI","BK4548","BK4535","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644644083","title":"Denali Therapeutics to sell rare pediatric disease priority review voucher for $195 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644644083","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644644083?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:05","pubTimestamp":1781784326,"startTime":"0","endTime":"0","summary":"Denali Therapeutics agreed to sell a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 195 million.The voucher was awarded following FDA accelerated approval of AVLAYAH  for Hunter syndrome in March 2026.Proceeds are slated to fund development of Denali’s TransportVehicle-enabled pipeline in lysosomal storage disorders and neurodegenerative diseases.Closing remains subject to customary conditions, including expiration of the Hart-Scott Rodino waiting period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1ZhvYs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","DNLI","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083355","title":"Denali Therapeutics - to Sell Rare Pediatric Disease Priority Review Voucher for $195 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083355?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:00","pubTimestamp":1781784001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUA89LRDF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4548","BK4535","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643828757","title":"Denali Therapeutics (DNLI) Receives a Buy from UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2643828757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643828757?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:36","pubTimestamp":1781613361,"startTime":"0","endTime":"0","summary":"In a report released today, Michael Yee from UBS maintained a Buy rating on Denali Therapeutics, with a price target of $25.00. According to TipRan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/denali-therapeutics-dnli-receives-a-buy-from-ubs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/denali-therapeutics-dnli-receives-a-buy-from-ubs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1863844749.USD","BK4118","LU1829250122.USD","BK4534","BK4535","BK4139","BK4585","LU1863844665.USD","IE0034235071.USD","BK4588","BK4548","UBS","DNLI","LU3187612489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640317159","title":"Denali Therapeutics shareholders elect three Class III directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640317159","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640317159?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:06","pubTimestamp":1780567595,"startTime":"0","endTime":"0","summary":"Denali Therapeutics held its annual shareholder meeting on June 3, 2026.Shareholders selected three directors to serve through the 2029 annual meeting.Shareholders backed a non-binding advisory resolution on the company’s named executive officers’ compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLWzy9r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","DNLI","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640971034","title":"Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2640971034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640971034?lang=en_us&edition=fundamental","pubTime":"2026-06-03 15:30","pubTimestamp":1780471800,"startTime":"0","endTime":"0","summary":"Antibody drugs that treat Alzheimer's disease have been on the market for several years. Their benefits are slight. One reason is the body's protective blood-brain barrier, which blocks 99% of a dose from reaching the brain.The drug industry has been working on tricks to shuttle drugs through that barrier, and the results will become apparent this year.Those working on brain-shuttling technologies include big names like Eli Lilly, Novartis, Biogen, and AbbVie, as well as smaller specialists like BioArctic, Alector, Voyager Therapeutics, and Sangamo Therapeutics. But leading the pack are Denali Therapeutics, which got the first U.S. approval for a shuttle-enhanced drug in March; and Roche Holding -- which is in pivotal trials with its barrier-crossing Alzheimer's antibody.Success with these products could yield annual sales above $13 billion for Roche and turn around the fortunes of the biotechs.Early studies showed that the shuttle-delivered trontinemab reached concentrations in the br","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","BK4548","RHHBY","BK4139","DNLI","BK4535","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639671594","title":"A Look At Denali Therapeutics (DNLI) Valuation After Phase 2b Trial Failure Refocuses Attention On Its Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2639671594","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639671594?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:06","pubTimestamp":1780070785,"startTime":"0","endTime":"0","summary":"Investor focus turns to Denali Therapeutics after trial setback\nDenali Therapeutics (DNLI) is back in focus after a Phase 2b study failed, prompting investors to reassess the stock around its remaining neurodegenerative and lysosomal disease pipeline, as highlighted by Morgan Stanley.\nSee our latest analysis for Denali Therapeutics.\nDespite the recent trial setback, Denali Therapeutics' 1 day share price return of 3.66% and 7 day share price return of 8.55% suggest short term buying interest...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/a-look-at-denali-therapeutics-dnli-valuation-after-phase-2b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/a-look-at-denali-therapeutics-dnli-valuation-after-phase-2b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","DNLI","BK4548","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638545085","title":"Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2638545085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638545085?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:29","pubTimestamp":1779809345,"startTime":"0","endTime":"0","summary":"Denali Therapeutics' (DNLI) investors will now look at its other pipeline assets and broader platform validation after its phase 2b trial for BIIB122 treating idiopathic Parkinson's disease failed to ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2023251221.USD","LU2271345857.HKD","LU0158827781.USD","LU1064131342.USD","LU1668664300.SGD","BK4588","BK4548","BK4007","LU1732799900.SGD","LU0528227936.USD","LU1548497426.USD","LU2357305700.SGD","LU2089283258.USD","LU0882574139.USD","BK4534","LU1732800096.USD","LU1989772923.USD","LU2264538146.SGD","BK4585","LU0267386448.USD","LU1791710582.SGD","BK4581","LU0158827948.USD","LU1720051017.SGD","LU0225283273.USD","LU2487616109.SGD","LU0006306889.USD","LU0971096721.USD","LU1720051108.HKD","LU0234570918.USD","LU0314104364.USD","BK4504","LU0390134368.USD","IE00BZ1G4Q59.USD","LU0912757837.SGD","LU1791710400.SGD","LU0106831901.USD","LENZ","DNLI","LU1244550494.USD","BK4539","LU1363072403.SGD","BK4127","LU0106261372.USD","LU2028103732.USD","LU2347655156.SGD","BK4516","LU0557290698.USD","LU1244550577.SGD","LU1162221912.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637789348","title":"Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Intuitive Surgical (ISRG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637789348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637789348?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:01","pubTimestamp":1779462116,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Denali Therapeutics (DNLI) and Intuitive Surgical (I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-denali-therapeutics-dnli-intuitive-surgical-isrg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-denali-therapeutics-dnli-intuitive-surgical-isrg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","BK4139","LU0079474960.USD","IE00B19Z9505.USD","LU1983299246.USD","LU2106854487.HKD","LU0823416689.USD","LU2265009873.SGD","LU1868836757.USD","LU2023250843.SGD","IE00B19Z8X17.USD","ISUL","LU0390134368.USD","BK4585","LU2324357040.USD","BK4548","LU0354030511.USD","LU0122379950.USD","IE00BYQQ9H92.USD","LU1023059063.AUD","LU2063271972.USD","IE00BFXG0V08.USD","LU0289739699.SGD","LU1923623000.USD","LU1057294990.SGD","LU1061106388.HKD","LU2125909247.SGD","LU1923622614.USD","LU1868836591.USD","LU0354030438.USD","LU0097036916.USD","LU0238689110.USD","LU1951200564.SGD","LU2125909593.SGD","BK4588","LU0061475181.USD","LU1974910355.USD","LU2023250504.SGD","LU2112291526.USD","BK4082","LU0823434583.USD","LU1366192091.USD","LU1868837136.USD","IE00B19Z8W00.USD","LU1917777945.USD","LU1989764748.USD","IE00B5TLWC47.USD","LU2433249047.HKD","DNLI","LU0096364046.USD","LU1868837300.USD","BK4504","ISRG","LU1951198990.SGD","LU1804176565.USD","LU1989764664.SGD","LU0882574055.USD","LU0823434740.USD","LU1868836914.USD","LU0114720955.EUR","LU0432979614.USD","BK4534","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637319930","title":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2637319930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637319930?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:41","pubTimestamp":1779450076,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL6N41Z0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909593.SGD","LU0266013472.USD","BK4525","BK4007","LU0859254822.USD","LU0211331839.USD","BK4155","BK4566","LU0203347892.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU1989772923.USD","LU1066051498.USD","LU0106261372.USD","LU1804176565.USD","SG9999014542.SGD","LU1861559042.SGD","LU1066051225.USD","LU1037948897.HKD","LU2361044949.HKD","LU2237438978.USD","LU2210149790.SGD","MRK","ROST","LU0965509283.SGD","LU2361045086.USD","LU1430594728.SGD","LU2491050154.USD","LU1162221912.USD","LU0965508806.USD","LU0238689110.USD","LU2404859741.USD","QBY","IE00BSNM7G36.USD","LU2491050071.SGD","LU0098860793.USD","IE00BN8TJ469.HKD","SG9999015358.SGD","IE00B2B36J28.USD","LU1235294995.USD","LU1048588211.SGD","SG9999014559.SGD","RGTI","LU1069347547.HKD","LU0289739699.SGD","LU1989771016.USD","LU1935042991.SGD","LU1291159041.SGD","LU2125154778.USD","BK4505","LU1093756325.SGD","LU1934455277.USD","BK4551","LU2265009873.SGD","LU2517655291.USD","BK4585","LU2361044865.SGD","LU1861558580.USD","LU2112291526.USD","LU2468319806.SGD","LU2552382215.SGD","LU2404859667.USD","RGTX","IE00BJT1NW94.SGD","SG9999014567.USD","BK4588","IE00BLSP4452.SGD","BK4558","LU1989772840.SGD","BK4127","LU0477156953.USD","LU0061475181.USD","LU0320765489.SGD","BK4139","BK4085","SG9999014575.USD","EL","LU0006306889.USD","LU1116320901.HKD","BK4017","LU0861579265.USD","BK4608","LU2095319765.USD","LU2125154935.USD","LU1061106388.HKD","LU2106854487.HKD","BK4504","LU0203345920.USD","LU1201861249.SGD","QBTX","SG9999001176.SGD","LU1718418525.SGD","BK4581","LU1861215975.USD","LU2264538146.SGD","LU0348767384.USD","IE000M9KFDE8.USD","IE00BFTCPJ56.SGD","LU0823417737.USD","IE0002141913.USD","LU1941712348.USD","RGTU","LU0950375773.USD","LU2552382132.HKD","LU2461242641.AUD","LU1066051811.HKD","LU1929549753.HKD","LU0823417653.USD","LU0965509010.AUD","LU1974910355.USD","LU0234572021.USD","SG9999015341.SGD","LU1057294990.SGD","LU1989773731.SGD","LU2517655028.SGD","LU0965509101.SGD","LU0432979614.USD","LU1934455863.HKD","LU0868494708.USD","LU2506951875.HKD","LU0265550946.USD","LU0122379950.USD","SG9999001176.USD","BK4183","BK4526","IE00BLSP4239.USD","LU0868494617.USD","LU1585245621.USD","IE0009356076.USD","LU2023250504.SGD","NGEN","BJ","LU1934455194.USD","BK4559","SG9999002232.USD","LU0081259029.USD","LU1323610961.USD","LU1988902786.USD","IE0004445239.USD","LU0208291251.USD","BK4509","LU2506951958.HKD","LU0348766576.USD","RGYY","LU1935043536.SGD","LU0719512351.SGD","LU2290526834.HKD","BK4141","LU1035773651.USD","LU0690374961.EUR","LU2360032135.SGD","LU1064131342.USD","LU1037948541.HKD","LU2210150020.SGD","BK4613","LU1923622614.USD","LU0640476718.USD","SG9999002463.SGD","PPTA","LU0942090050.USD","LU0980610538.SGD","FUTG","BK4602","IE0009355771.USD","LU0130102774.USD","LU0320765646.SGD","LU1691799644.USD","LU1941712264.USD","LU2023250843.SGD","LU2552382058.USD","LU0690374615.EUR","BK4548","IE00B4R5TH58.HKD","LU1823568750.SGD","LU2089984988.USD","LU1981816686.USD","DNLI","BK4516","LU0314104364.USD","LU1571399168.USD","BK4023","LU2324357040.USD","IE00B5949003.HKD","SG9999013999.USD","SGXZ57979304.SGD","BK4094","FUTU","IE00BBT3K403.USD","LU0082616367.USD","BK4550","BK4524","BK4528","LU2357627491.SGD","LU1116320737.USD","BK4534","LU0648001328.SGD","LU1989763005.USD","LU1861220033.SGD","WDAY","BK4554","LU2433249047.HKD","LU0130517989.USD","LU0058720904.USD","SG9999001440.SGD","TTWO","LU1699723380.USD","LU1066053197.SGD","LU1093756168.USD","BK4533","QBTZ","BK4503","LU2360107168.USD","LU0265550359.USD","BK4532","LU0985320562.USD","LU1917777945.USD","LU2491049909.HKD","LU2506952097.USD","RGTZ","SG9999002224.SGD","QBTS","LU2125909247.SGD","IE00B1BXHZ80.USD","ZM","LU0072462343.USD","LU2517655374.HKD","LU1280957306.USD","BK4535","LU1983299246.USD","LU2506952170.USD","LU1023059063.AUD","LU1046421795.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637390075","title":"Denali Therapeutics Shares Fall 7.3% Premarket After Scrapping Development of Parkinson's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2637390075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637390075?lang=en_us&edition=fundamental","pubTime":"2026-05-22 17:44","pubTimestamp":1779443068,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nFWN41Y184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","BK4548","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637368586","title":"Biogen, Denali Say Parkinson's Drug Didn't Meet Trial Endpoints -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2637368586","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637368586?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:00","pubTimestamp":1779404400,"startTime":"0","endTime":"0","summary":"A drug being developed by Biogen and Denali Therapeutics to treat Parkinson's didn't slow down progression of the disease in a recent trial.The drug companies said Thursday they are discontinuing further development of BIIB122 in idiopathic Parkinson's disease based on the results.Denali shares retreated 7% to $18, while Biogen's stock declined 1% to $187.49.BIIB122, which is in a Phase 2b trial to treat early-stage Parkinson's, failed to meet its primary or secondary endpoints in the study.The trial involved 648 participants from ages 30 to 80 with early-stage Parkinson's. They received treatment for at least 48 weeks and up to 144 weeks.BIIB122 was an investigational small molecule inhibitor of LRRK2, a gene that has been linked to Parkinson's.Denali will continue to conduct a Phase 2a study evaluating the small molecular inhibitor in carriers of a pathogenic LRRK2 variant.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","IE00B19Z9P08.USD","BK4585","BK4533","BK4588","IE00B894F039.SGD","LU0109394709.USD","LU0234570918.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4548","BIIB","LU0320765992.SGD","DNLI","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637350532","title":"Denali, Biogen scrap BIIB122 Parkinson’s program after Phase 2b LUMA miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2637350532","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637350532?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:03","pubTimestamp":1779400997,"startTime":"0","endTime":"0","summary":"Denali Therapeutics disclosed topline results from the Phase 2b LUMA study of BIIB122  in early-stage Parkinson’s disease, with detailed findings set for presentation at a future scientific conference.The trial failed to show a clinical benefit versus placebo, missing both the main goal and key follow-on measures.Biogen and Denali will stop further development of BIIB122 for idiopathic Parkinson’s disease, despite the drug showing expected biological activity signals and an acceptable safety profile.Denali will continue the Phase 2a BEACON study in Parkinson’s patients who carry a pathogenic LRRK2 variant, with data expected in the first half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL4blgcJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","DNLI","BK4533","BK4535","BK4532","BK4139","IE00B19Z9Z06.USD","LU0109394709.USD","LU0889565916.HKD","BK4548","IE00B19Z9P08.USD","BIIB","LU0320765992.SGD","LU0234570918.USD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637503623","title":"Biogen and Denali Therapeutics Provide Update on Phase 2B Luma Study of Biib122 (Dnl151) in Early-Stage Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2637503623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637503623?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:00","pubTimestamp":1779400801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUABBPN0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","IE00B19Z9Z06.USD","BIIB","LU0320765992.SGD","IE00B894F039.SGD","BK4533","BK4585","BK4535","BK4588","LU0234570918.USD","LU0109394709.USD","LU0889565916.HKD","IE00B19Z9P08.USD","DNLI","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637503263","title":"Biogen - Data From Beacon Study Anticipated in First Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2637503263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637503263?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:00","pubTimestamp":1779400801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUABBPN0D:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","IE00B894F039.SGD","IE00B19Z9Z06.USD","BK4548","LU0109394709.USD","LU0320765992.SGD","BK4535","BK4532","BK4585","BIIB","DNLI","IE00B19Z9P08.USD","LU0234570918.USD","BK4139","BK4588","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637350329","title":"Biogen - Biib122 Generally Well Tolerated With Acceptable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2637350329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637350329?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:00","pubTimestamp":1779400801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUABBPN0D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z9P08.USD","BK4535","LU0889565916.HKD","BK4139","BK4585","IE00B19Z9Z06.USD","LU0109394709.USD","BK4548","DNLI","BIIB","LU0234570918.USD","LU0320765992.SGD","IE00B894F039.SGD","BK4588","BK4533","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637350325","title":"Biogen - Denali Continues Phase 2a Beacon Study in Lrrk2 Variant Carriers","url":"https://stock-news.laohu8.com/highlight/detail?id=2637350325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637350325?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:00","pubTimestamp":1779400801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUABBPN0D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z9P08.USD","BK4585","DNLI","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4588","LU0109394709.USD","LU0234570918.USD","LU0889565916.HKD","BK4532","BK4535","IE00B894F039.SGD","BK4548","BK4533","BIIB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637350323","title":"Biogen - Phase 2B Luma Study of Biib122 Does Not Meet Primary or Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2637350323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637350323?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:00","pubTimestamp":1779400801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUABBPN0D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0234570918.USD","BK4532","LU0109394709.USD","DNLI","LU0320765992.SGD","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4139","LU0889565916.HKD","BK4585","BK4535","BK4548","BK4588","IE00B19Z9Z06.USD","BK4533","BIIB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.denalitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.2729},{"period":"3month","weight":0.2581},{"period":"6month","weight":0.5968},{"period":"1year","weight":0.8624},{"period":"ytd","weight":0.5736}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.068767},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.02262},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.087803},{"month":4,"riseRate":0.555556,"avgChangeRate":0.007711},{"month":5,"riseRate":0.777778,"avgChangeRate":0.055944},{"month":6,"riseRate":0.666667,"avgChangeRate":0.078033},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.039924},{"month":8,"riseRate":0.625,"avgChangeRate":0.067423},{"month":9,"riseRate":0.5,"avgChangeRate":0.021936},{"month":10,"riseRate":0.375,"avgChangeRate":-0.037447},{"month":11,"riseRate":0.625,"avgChangeRate":0.13715},{"month":12,"riseRate":0.375,"avgChangeRate":0.011033}],"exchange":"NASDAQ","name":"Denali Therapeutics Inc.","nameEN":"Denali Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Denali Therapeutics Inc.,DNLI,Denali Therapeutics Inc.股票,Denali Therapeutics Inc.股票老虎,Denali Therapeutics Inc.股票老虎国际,Denali Therapeutics Inc.行情,Denali Therapeutics Inc.股票行情,Denali Therapeutics Inc.股价,Denali Therapeutics Inc.股市,Denali Therapeutics Inc.股票价格,Denali Therapeutics Inc.股票交易,Denali Therapeutics Inc.股票购买,Denali Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}